- Home
- XFOR vs BYSI Comparison
XFOR vs BYSI Comparison
Compare XFOR & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- BYSI
- Stock Information
- Founded
- XFOR 2014
- BYSI 2010
- Country
- XFOR United States
- BYSI United States
- Employees
- XFOR N/A
- BYSI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- BYSI Health Care
- Exchange
- XFOR Nasdaq
- BYSI Nasdaq
- Market Cap
- XFOR 84.3M
- BYSI 80.6M
- IPO Year
- XFOR N/A
- BYSI 2017
- Fundamental
- Price
- XFOR $3.64
- BYSI $1.81
- Analyst Decision
- XFOR Strong Buy
- BYSI
- Analyst Count
- XFOR 3
- BYSI 0
- Target Price
- XFOR $34.17
- BYSI N/A
- AVG Volume (30 Days)
- XFOR 10.6M
- BYSI 27.4K
- Earning Date
- XFOR 08-08-2025
- BYSI 08-13-2025
- Dividend Yield
- XFOR N/A
- BYSI N/A
- EPS Growth
- XFOR N/A
- BYSI N/A
- EPS
- XFOR N/A
- BYSI N/A
- Revenue
- XFOR $32,774,000.00
- BYSI N/A
- Revenue This Year
- XFOR $1,313.84
- BYSI N/A
- Revenue Next Year
- XFOR N/A
- BYSI N/A
- P/E Ratio
- XFOR N/A
- BYSI N/A
- Revenue Growth
- XFOR 5721.31
- BYSI N/A
- 52 Week Low
- XFOR $1.35
- BYSI $0.98
- 52 Week High
- XFOR $26.83
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- XFOR 51.62
- BYSI 44.19
- Support Level
- XFOR $3.57
- BYSI $1.67
- Resistance Level
- XFOR $4.83
- BYSI $1.84
- Average True Range (ATR)
- XFOR 0.55
- BYSI 0.12
- MACD
- XFOR -0.05
- BYSI 0.01
- Stochastic Oscillator
- XFOR 26.94
- BYSI 40.79
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.